FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Fibroblast growth factor receptor 4 (FGFR4) plays a critical role in cancer progression involving in tumor proliferation, invasion, and metastasis. This study clarified the role of FGFR4-Arg388 variant in gastric cancer (GC), and more importantly highlighted the possibility of this single nucleotide polymorphism (SNP) as potential therapeutic targets. Materials and Methods FGFR4 polymorphism was characterized in advanced GC patients to perform statistical analysis. FGFR4-dependent signal pathways involving cell proliferation, invasion, migration, and resistance to oxaliplatin (OXA) in accordance with the SNP were also assessed in transfected GC cell lines. Results Among 102 GC patients, the FGFR4-Arg388 patients showed significantly higher tumor stage (p=0.047) and worse overall survival (p=0.033) than the Gly388 patients. Immunohistochemical results showed that FGFR4-Arg388 patients were more likely to have higher vimentin (p=0.025) and p-STAT3 (p=0.009) expression compared with FGFR4-Gly388 patients. In transfected GC cells, the overexpression of FGFR4-Arg388 variant increased proliferation and invasion of GC cells, increasing resistance of GC cells to OXA compared with cells overexpressing the Gly388 allele. Conclusion The exploration mechanism may be through FGFR4-Arg388/STAT3/epithelial to mesenchymal transition axis regulating pivotal oncogenic properties of GC cells. The FGFR4-Arg388 variant may be a biomarker and a candidate target for adjuvant treatment of GC.
Abstract
Purpose Fibroblast growth factor receptor 4 (FGFR4) plays a critical role in cancer progression involving in tumor proliferation, invasion, and metastasis. This study clarified the role of FGFR4-Arg388 variant in gastric cancer (GC), and more importantly highlighted the possibility of this single nucleotide polymorphism (SNP) as potential therapeutic targets. Materials and Methods FGFR4 polymorphism was characterized in advanced GC patients to perform statistical analysis. FGFR4-dependent signal pathways involving cell proliferation, invasion, migration, and resistance to oxaliplatin (OXA) in accordance with the SNP were also assessed in transfected GC cell lines. Results Among 102 GC patients, the FGFR4-Arg388 patients showed significantly higher tumor stage (p=0.047) and worse overall survival (p=0.033) than the Gly388 patients. Immunohistochemical results showed that FGFR4-Arg388 patients were more likely to have higher vimentin (p=0.025) and p-STAT3 (p=0.009) expression compared with FGFR4-Gly388 patients. In transfected GC cells, the overexpression of FGFR4-Arg388 variant increased proliferation and invasion of GC cells, increasing resistance of GC cells to OXA compared with cells overexpressing the Gly388 allele. Conclusion The exploration mechanism may be through FGFR4-Arg388/STAT3/epithelial to mesenchymal transition axis regulating pivotal oncogenic properties of GC cells. The FGFR4-Arg388 variant may be a biomarker and a candidate target for adjuvant treatment of GC.
참고문헌 (30)
- Katoh M, "Genetic alterations of FGF receptors : an emerging field in clinical cancer diagnostics and therapeutics", Expert Rev Anticancer Ther, 10, pp.1375~1379 (2010)
- Li J, "The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer", Tumour Biol, 37, pp.6881~6891 (2016)
- Ye Y, "Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer", Tumour Biol, 37, pp.3185~3195 (2016)
- Ye Y, "The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression", Ann Surg Oncol, 17, pp.3354~3361 (2010)
- Chou CH, "Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility", Oncotarget, 8, pp.96225~96238 (2017)
- Ezzat S, "FGFR4 polymorphic alleles modulate mitochondrial respiration : a novel target for somatostatin analog action in pituitary tumors", Oncotarget, 8, pp.3481~3494 (2017)
- Whittle SB, "A polymorphism in the FGFR4 gene is associated with risk of neuroblastoma and altered receptor degradation", J Pediatr Hematol Oncol, 38, pp.131~138 (2016)
- Morimoto Y, "Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma", Cancer, 98, pp.2245~2250 (2003)
- Streit S, "FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients", Br J Cancer, 94, pp.1879~1886 (2006)
- Yu W, "FGFR-4 Arg(3)(8)(8)enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling", Clin Cancer Res, 17, pp.4355~4366 (2011)
- Jalali S, "Role of mTOR inhibitors in growth hormone-producing pituitary adenomas harboring different FGFR4 genotypes", Endocrinology, 157, pp.3577~3587 (2016)
- Ulaganathan VK, "Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants", Mol Cell Oncol, 3, pp.e1145176~ (2016)
- Ezzat S, "The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes", Cell Metab, 17, pp.929~940 (2013)
- Sugiyama N, "FGF receptor-4(FGFR4)polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex", Proc Natl Acad Sci U S A, 107, pp.15786~15791 (2010)
- 조상희, "FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition", Cancer Research and Treatment, 49(3), pp.766~777 (2017), 대한암학회
- Quintanal-Villalonga A, "The FGFR4-388arg variant promotes lung cancer progression by N-cadherin induction", Sci Rep, 8, pp.2394~ (2018)
- Edge SB, "The American Joint Committee on Cancer : the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)
- Thussbas C, "FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer", J Clin Oncol, 24, pp.3747~3755 (2006)
- Myoteri D, "Prognostic evaluation of vimentin expression in correlation with Ki67 and CD44 in surgically resected pancreatic ductal adenocarcinoma", Gastroenterol Res Pract, 2017, pp.9207616~ (2017)
- Gao H, "Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer", Tumour Biol, 39, pp.1010428317698368~ (2017)
- Zhang S, "Co-ordinated overexpression of SIRT1 and STAT3 is associated with poor survival outcome in gastric cancer patients", Oncotarget, 8, pp.18848~18860 (2017)
- Serra S, "The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy", Cancer Res, 72, pp.5683~5691 (2012)
- Quintanal-Villalonga A, "Prognostic role of the FGFR4-388Arg variant in lung squamous-cell carcinoma patients with lymph node involvement", Clin Lung Cancer, 18, pp.667~674 (2017)
- 심현정, "The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy", Cancer Research and Treatment, 48(1), pp.71~79 (2016), 대한암학회[DOI]
- Gao L, "FGF19", FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib, 2017, pp.36, 8~
- Calo V, "STAT proteins : from normal control of cellular events to tumorigenesis", J Cell Physiol, 197, pp.157~168 (2003)
- Okabe M, "MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma", Clin Cancer Res, 12, pp.3902~3907 (2006)
- Sullivan NJ, "Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells", Oncogene, 28, pp.2940~2947 (2009)
- Cheng GZ, "Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function", J Biol Chem, 283, pp.14665~14673 (2008)
- Zang C, "IL-6", STAT3, Oncotarget, pp.2017, 8[DOI]